Novartis apologizes for slow reporting

Share this article:

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events associated with its leukemia drugs Gleevec and Tasigna.

Reuters reports that Novartis knew there was a problem, because complaints started surfacing in April 2013, but that the drugmaker did not inform Japan's agency until April of this year. The ministry tells Reuters the rule is that companies need to tell the health agency about adverse events within a month.

Thursday's news is another blow for the company's local imageā€”a former Novartis employee has been accused of falsifying data in promotions for the blood pressure drug Diovan.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions